Neuralstem (NASDAQ:CUR) had its target price lowered by analysts at S&P Equity Research from $2.26 to $1.91 in a report released on Thursday.
Shares of Neuralstem (NASDAQ:CUR) traded up $0.09 during mid-day trading on Thursday, reaching $1.91. The company’s stock had a trading volume of 504,100 shares, compared to its average volume of 328,714. Neuralstem has a one year low of $0.88 and a one year high of $6.60. The firm has a market cap of $33.98, a price-to-earnings ratio of -1.15 and a beta of 1.60.
An institutional investor recently raised its position in Neuralstem stock. National Asset Management Inc. increased its position in Neuralstem, Inc. (NASDAQ:CUR) by 9.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,985 shares of the company’s stock after buying an additional 1,937 shares during the quarter. National Asset Management Inc. owned about 0.19% of Neuralstem worth $134,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 7.05% of the company’s stock.
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with MarketBeat.com's FREE daily email newsletter.